Exits

EpiTherapeutics

Discovery of new pharmaceuticals for the treatment of cancer within the field of epigenetics.

Invested in 2010

Acquired by Gilead in 2015

Based in Foster City, California, USA 

Lundbeckfonden Emerge

News

Dermtreat Announces First Patient Dosed in Phase 2b Clinical Trial of Rivelin Clobetasol for Oral Lichen Planus
28. July 2018
Dermtreat secures GMP manufacturing
4. September 2017
Dermtreat Raises USD 17.7 mill. From Sofinnova Ventures, Novo A/S and Lundbeckfonden
8. May 2017